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Plasmacytomas are readily induced in the inbred BALB/c strain of mice by 
the intraperitoneal  injection of mineral  oils or branched chain alkanes such as 
2, 6,  10,  14 tetramethylpentadecane  (pristane).  These tumors provide a source 
for a  large number  of different homogeneous immunoglobulins  which  are  the 
products of a  nonpolymorphic mammalian  genome.  Myeloma proteins  in our 
laboratory and in the laboratory of Dr. Melvin Cohn of the Salk Institute have 
been screened for binding activity with a variety of antigens.  From these stud- 
ies have emerged groups of proteins that bind the same antigens.  Further im- 
munochemical analysis of the binding interactions has revealed that an antigen 
bound by several proteins is usually bound via the same haptenic group. Three 
major  groups  of antigen-binding  myeloma proteins,  defined by their  hapten- 
binding activity are, the a(1 --* 3) dextran group (1, 2), the phosphorylcholine 
group (3, 4, 5), and the ~-(1 ~  6)-D-galactan  group (6, 7).  With  the  a(1--~3) 
dextran group all of  the  proteins  have  been  shown  to  contain  lambda  type 
light  chains  of identical  amino  acid  sequence  (2, 8). The  proteins,  however, 
differ  from each  other  by possessing  individual  antigenic  (idiotypic)  specific- 
ities  and  different  Va  polypeptide  chains  (2,  8).  In  the  phosphorylcholine 
group  at least  three  distinct  subgroups of light  chains can be found based on 
widely different NH=-terminal  sequences (9); one of these  subgroups  contains 
eight very closely related proteins that also share the same individual  antigenic 
specificity  suggesting  structural  identity (4,  5).  In  the  present  study we de- 
scribe structural  and antigenic studies on six IgA myeloma proteins of BALB/c 
origin with anti-3-(1 ~  6)-D-galactan activity. 
Materials and Methods 
Origin of Tumors.--The plasmacytomas JPC1, SAPC 10, XRPC 24, XRPC 44, TEPC 191, 
and J539 which produced the corresponding myeloma proteins (J1, St0, X24, X44, T191, and 
J539) used in this study were induced in strain BALB/c mice by three bimonthly intraperi- 
toneal injections of 0.5 ml mineral oil or pristane  (Aldrich Chem. Co., Inc., Milwaukee, Wis.) 
(10, 11). The J539 plasmacytoma was induced at the Salk Institute and was kindly given to us 
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for this study by Dr. Melvin Cohn. The other five tumors were induced at the National Insti- 
tutes of Health. 
Detection of Galactan-Binding Activity.--The  specificity of the  J539 myeloma protein was 
discovered by screening against protein antigens to which p-azophenyl-/~-D-galactoside had 
been covalently bonded (12).  Subsequently, we found that the J539 protein also precipitated 
with  larchwood  arabinogalactan  and  gum  ghatti,  both  polysaccharides  having  multiple 
/3-(1 ~  6)-D-galactopyranosyl  linkages (6).  The myeloma  proteins  in  this laboratory  were 
identified  in  screening studies using  larchwood  arabinogalactan  (Calbiochem,  San  Diego, 
Calif.) and gum ghatti solutions (Fisher Scientific Co., Pittsburgh, Pa.). 
Ascites or serum from mice with primary plasmacytomas was reacted by the micro-Ouchter- 
lony method with arabinogalactan (2 mg/ml) or gum ghatti (1 mg/ml) and found to give strong 
lines of precipitation. Other antigens which are precipitated by these proteins have been iso- 
lated from natural products in the laboratory and include an extract of the hardwood bedding 
used in the mouse cages and an extract of milling wheat (6) (Fig. 1). 
FIG.  1.  Precipitation of six antigalactan IgA myeloma proteins with an extract of hardwood 
bedding. 
Source of Myeloma Proteins.--To produce large quantities of myeloma proteins 105 to 106 
plasmacytoma cells dissociated from a subcutaneous tumor were transplanted intraperitoneally 
into mice which had received 1 or 2 intraperitoneal injections of 0.5 ml pristane 7-60 days be- 
fore  transplantation (13).  The  tumor lines themselves were  maintained by  serial  subcuta- 
neous passage using the trochar method (14) in BALB/e mice. 
For production of large amounts of ascites the tumors were grown in (BALB/c X  DBA/2) 
F1 hybrids. These mice, when primed with pristane, produced voluminous quantifies of ascites. 
The ascites was removed by paracentesis with a 16 gauge needle. Several collections were made 
from each mouse. An average mouse produced 20--30 ml of ascites. 
The myeloma proteins used in the hemagglutination and amino acid sequence studies were 
isolated from whole ascites by affinity chromatography using Sepharose-bovine serum albumin 
(BSA)-p-azo phenyl/3-n-thiogalactopyranoside columns according to the methods previously 
described (7, 15). The proteins isolated by this method were shown to be pure by immunoelec- 
trophoresis using rabbit antimouse serum. 
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munization of strain AL/N or A/J mice with mydoma protein which had been partially puri- 
fied by ammonium sulfate precipitation from serum or by washed immune precipitates made 
by  precipitating  the  myeloma protein from  ascites with a  solution of  arabinogalactan  (2 
mg/ml).  Preparations  of  myeloma proteins were  mixed with complete  Freund's adjuvant 
(CFA) I and were injected into each mouse at six different sites. For the initial injection each 
mouse received approximately 400 Izg. Mter three injections with CFA the rest of the injec- 
tions were given with incomplete Freund's adjuvant. 
Serum was harvested by orbital puncture after day 30 and was shown to precipitate with 
the immunizing protein. For each protein the sera from five or more mice were individually 
collected. Three different sera were evaluated for each protein in the inhibition of hemagglu- 
fination test. 
Heavy Chain Class of Mydoma Proteins.--All six of the galactan-binding myeloma proteins 
in this study were IgA class proteins as determined by a specific rabbit antimouse IgA serum. 
Inhibition  of Hemmagglutination (///).--Sheep red blood cells (SRBC) were coupled with 
immunoadsorbant-purified myeloma protein by the CrCla method (16). 0.1 ml Of a  10 #g/ml 
solution of protein in 0.85% NaC1 was added to 0.1 ml of 0.05% solution of CrCla and to this 
mixture 0.1 ml of a 50% suspension of washed SRBC was quickly added and allowed to react 
for 2-4 rain at room temperature. 
Idiotypic antisera for each protein were tested for hemagglutinating (HA) activity in the 
microtiter system and the limiting dilution was determined. A concentration of serum four 
times the end point in the HA test was used in the HI studies. In the HI test purified myeloma 
proteins were serially diluted and to each dilution a constant amount of antiserum was added 
followed by the addition of coupled SRBC. The end point reported is the reciprocal of the 
highest log2 dilution of myeloma protein that gave complete inhibition. 
Chain Separation.--Heavy and light chains were separated by partial sulfitolysis  2 followed 
by chromatography on Sephadex G-100 in 6 M urea-1 M acetic acid. Chains were used for se- 
quence studies either as the sulfitolyzed product or were fully reduced with 0.01  M  dithio- 
threitol in 5 M  guanidine-0.05 M Tris-HC1 pH 8.2 (2 h, 37°C) and alkylated with 0.02 M  14C 
iodoacetamide (30 rain, 37°C). 
NH2 Terminal Sequence Determination,--Sequence  analyses were performed on a Beckman 
Model 890C Protein Sequencer (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) 
using the standard Beckman DMAA peptide program. 10-15 mg of polypeptide chain were dis- 
solved in 0.5 ml acetic acid for application to the sequencer. The thiazolinone derivative ob- 
tained after each degradation cycle was converted to the phenylthiohydantoin (PTH) by in- 
cubation in 1 N HC1 at 80°C for 10 min. The PTH's were extracted twice with ethyl acetate and 
dried under a  stream of N2 • 
PTH-amino acids were identified by gas chromatography on SP400 columns (17)  before 
and after silylation and/or thin-layer chromotography (18), and/or amino acid analysis. PTH 
derivatives were hydrolyzed to their respective amino acids under vacuum in 6 N  HC1 con- 
taining 0.05% thiodiglycol for ~18 h at 140°C.  Hydriodic acid hydrolysis was performed ac- 
cording to the method of Smithies et al. (19). Cysteine was identified by scintillation counting 
of the 14C-labeled derivative. 
RESULTS 
Partial Aminoterminal Sequences.--The  NH2-terminal sequences of the light 
chains from the six galactan-binding proteins are presented in Table I. As may 
1 Abbreviations used in this paper: BSA, bovine serum albumin; CFA, complete Freund's 
adjuvant; HA, hemagglutinating activity; HI, inhibition of hemmagglutination; PTH, phenyl- 
thiohydantoin; SRBC, sheep red blood cells. 
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TABLE  T 
NH2-Terminal Sequences of  Mouse Anti-~/.6  Golocton  Proteins 
V L 
1  lO  20 
$10  Glu  lieu  Val  Leu  Thr  Gin  Ser  Pro  Ala  lieu  Thr  Ala  Ala Ser  Leu  Gly  Gin  Lys  Val  Thr  lieu  Thr  Cys 
X24 
X44 
T191 
J539 
30 
$10 
X24 
X44 
VH 
Glu  Val  Lys  Leu  Leu  Glu  Ser  Gly  Gly  GIy  Leu  Val  Gin  Pro  Gly  Gly  Ser  Leu  Lys  Leu  Ser  Cys  Ala  Ala {Ser)  Gly  Phe  Asp  Phe(Ser) 
.  (  }- 
T191 
J539 
J1  lieu 
be seen no differences were found in the first 23 residues of any of the light 
chains. The NH~-terminal sequences of the heavy chains from the six proteins 
were determined to residue 30 (Table I). Four of the chains (S10, T191, J539, 
and X44) had an identical sequence. The J1 heavy chain in contrast to the other 
five proteins had isoleucine instead of leucine at position five. Ileu was identified 
both by gas chromatography and amino acid analysis. Position 19 in the X24 H 
chain could not be identified. As Lys was identified at this position in the five 
other chains and since Lys is readily identified by amino acid analysis this posi- 
tion in X24 is occupied by an amino acid which we have not been able (for 
reasons not yet understood) to identify. 
Specificity  of Antisera.--The  antisera to each myeloma protein were tested 
in  the micro-Ouchterlony system for their ability to precipitate with ascites 
from each of the galactan-binding proteins  (Fig.  2).  AL or A/J mice strains 
used in preparing the antisera can form both idiotypic and anti-IgA allotypic 
antibodies to these proteins. Sera selected for the study precipitated strongly 
with the immunizing protein and weakly, if at all, with the other proteins. Only 
one antiserum (anti-J1)  was purely idiotypic by the precipitin tests  (Fig. 2). 
The anti-S10, T191, and anti-J539 antisera showed restricted activity an pre- 
cipitated strongly with immunizing antigen and one other of the proteins. Sev- 
eral anti-S10 antisera precipitated T191  and S10 suggesting by this  method 
shared idiotypic specificities.  Anti-T191 occasionally showed weak precipitating 
activity with S10. The anti-J539 cross-reacted with X44. Antisera to X24 and 
X44 reacted with all of the proteins (Fig. 2). The precipitin reactions, however, 
utilize large amounts of antibody and do not reflect the specificity of diluted 
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FIG. 2.  Seven ouchterlony patterns showing precipitation of myeloma  proteins with various 
antiserums. In each of the patterns the unabsorbed antiserum was placed in the center well and 
serum or ascites from tumor-bearing mice placed in the outer well. Two anti-S10 antisera are 
illustrated, both of which show cross-reactions  with T191. (For further description see text.) 
Hemmagglutination titers were determined for 15 of the antisera in the study 
for five types of coupled cells (Table II). As may be seen, the highest titers were 
always to the immunizing protein indicating the preponderant antibody in any 
given serum was directed to idiotypic determinants. Some of the antisera were 
essentially specific for the immunizing protein while others with high titers for 
the immunizing protein cross-reacted at low titer with several but not all of the 
other  proteins.  Antisera  prepared to  the  SAPC10  protein  cross-reacted  with 
TEPCI91 as suggested by the precipitin studies. 
Inhibition of Hemagglutination by Antigalactan Myeloma Proteins.--Using  di- 
lutions of the antisera ranging from ~00  to 1/~0,000 the antisera were found to 
contain only idiotypic specificities. First, at these dilutions none of the antisera 
were inhibitable by normal BALB/c serum. Second,  other IgA myeloma pro- 
teins of BALB/c origin which did not have anti-~-(1 --~ 6)-D-galactan-binding 1100  GALACTAN-BINDING  MYELOMA PROTEINS 
TABLE II 
Direct Hemagglutination of SRBC Coupled with Myeloma Proteins 
Antiserum  No.  Dilution 
Log2 HA titer to ceils coupled with myeloma proteins 
J1  SI0  X24  X44  T191 
Anti-J1 
Anti-SlO 
Anti-X24 
Anti-X44 
Anti-T191 
1  1:10  12  5  0  0  0 
2  1:10  6  0  0  0  0 
3  1:10  15  5  3  0  0 
1  1:50  0  12  0  0  4 
2  1:10  0  14  0  0  3 
3  1:10  0  16  0  0  1 
1  1:50  0  0  18  0  0 
2  1:10  0  0  10  0  0 
3  I:10  0  5  10  11  0 
1  1:10  0  0  0  24  0 
2  1:10  0  0  0  20  0 
3  1:10  0  3  0  24  0 
1  1:10  0  6  0  0  15 
2  1:10  0  9  0  4  14 
3  1:50  0  8  0  3  10 
activity were unable to inhibit the specific reactions.  Finally, using concentra- 
tions of myeloma protein for inhibition ranging from 125 to 500 #g/ml, all of the 
antisera were found to be individually specific (Table III). As may be seen in 
Table III most antisera at the concentrations tested were completely inhibited 
by dilutions that contained as little as 10  -1 to 10  -~ #g of the specific myeloma 
protein.  1 thousand to 10 thousand-fold excesses of the other myeloma proteins 
in the antigalactan group failed to inhibit. The results clearly indicate that each 
of the antisera when used at limiting dilution identifies on its homologous im- 
munizing myeloma protein an antigenic determinant not shared by any of the 
other proteins. One significant cross specificity was observed in one of the anti- 
sera prepared to S10 (Table III) that cross-reacted with T191. 
DISCUSSION 
The basic observations made in this study of six BALB/c IgA myeloma pro- 
teins with/~-(1 ~  6)-D-galactan-binding activity were (a) all of the light chains 
had the same aminoterminal sequence to residue Cys23; (b) four of the proteins 
had the same V~ aminoterminal sequence to residue 30, and the two other pro- 
teins differed from this  sequence at only one position.  The JPC1  protein  has 
isoleucine at position five instead of leucine which is found in all of the others 
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TABLE III 
Inhibition of Hemagglutination  of Idiotypic Antisera with Coupled SRBC by Mydoma Proteins 
that Bind [31 ~  6 D-Galactan 
Idiotyplc  No.  Max. conc.  Log2 titer of inhibitor giving complete inhibition 
antiserum* to:  antisera  inhibitor  JPC-1  SAPC10  XRPC24  XRPC44  TEPC19I  J539 
I.~g/ml 
JPC-1  1  125  8  ..... 
2  125  12  1  .... 
SAPC-10  1  500  --  14  --  --  8  -- 
2  125  --  12  .... 
XRPC24  2  125  1  2  11  --  --  -- 
1  125  --  3  12  --  --  -- 
XRPC44  1  125  --  2  --  12  --  -- 
1  125  --  1  --  11  --  -- 
TEPC191  4  125  ....  12-14  -- 
1  500  --  3  --  --  11  -- 
J539  1  125  --  2  --  --  --  12 
2  125  --  2  1  --  --  10 
-- equals no inhibition  observed. 
* Prepared in A/H mice. 
proteins possessed a unique individual  antigenic determinant which was demon- 
strable by an inhibition of hemagglutination method. 
The  observation that  these  six proteins are  idiotypically different implies 
that they all have different primary structures. The similarity  of the V kappa se- 
quence up to the Cys23 residue suggests the light chains in these proteins could 
be the same or nearly so. Kappa chains with the same aminotermina123  residues 
have been shown to  have 3-17  differences throughout the  remainder of  the 
chains (20, 21). These sequences, however, were done on light chains from mye- 
loma proteins with no known antigen-binding  activity. Proteins that all bind 
the same hapten may be much more similar to each other in primary structure 
due to the selective pressure to maintain the same antigen-binding  specificity. 
Therefore, the fact that all of the antigalactan proteins have the same amino- 
terminal Cys23 sequence suggests that this particular V kappa polypeptide se- 
quence is an essential component of anti-~-(1 --~ 6)-D-galactan-binding  proteins 
in the BALB/c mouse. This is analogous to findings with the mouse lambda 
chains from proteins with a(1 --* 3) dextran-binding  activity described by Wei- 
gert et al. (2, 8). In the antidextran system all of the proteins thus far studied 
have identical lambda chains. 
In contrast, light chains from phosphorylcholine-binding  proteins are repre- 
sented by at least three distinct germ line genes (9). We are currently under- 
taking a  complete sequence analysis of the V regions of the light chains of the 
galactan-binding  proteins to ascertain the types of variation (if any) which can 
be found among a group of apparently very similar proteins. 1102  GALACTAN-BINDING  MYELOMA  PROTEINS 
While less is known about heavy chain diversity in the mouse, partial amino 
acid sequences to residue 30 have indicated several subgroups, but the diversity 
in the amino terminal sequence appears to be far less than in the kappa chains 
(14, 20, 21). While the six Vn sequences were not identical they did appear to be 
closely related. In fact only two differences were noted among the six chains. A 
similar observation has been made for the heavy chains of phosphorylcholine- 
binding proteins. Of five chains studied four are identical through the first hy- 
pervariable region and the fifth has a single substitution at position 4.  3 
While  these partial  structural  studies  indicate  that  the  proteins have  ex- 
tensive similarities it was demonstrated with the very sensitive inhibition of 
hemagglutination method that each protein possessed an individual antigenic 
specificity. This therefore requires that the proteins have other primary struc- 
tural differences at some point beyond the aminoterminal sequence reported 
here. Thus, the antigalactan proteins do not resemble the group of BALB/c 
phosphorylcholine-binding myeloma proteins (the S63-TEPC15 group) which 
have the same individual antigenic specificities by both the precipitin (4) and 
the inhibition of hemagglutination techniques and which thus far have no de- 
monstrable primary structural differences. It is possible that the S63-TEPC15 
phosphorylcholine-binding proteins may in fact be composed of chains of identi- 
cal primary structure (9).  3 It should be noted at this point that in the phos- 
phorylcholine system several other protein types e.g. MOPC 167, McPC 603, 
and MOPC 511 have been identified which have light chains from completely 
different subgroups than the $63-T15 group. Clearly the antigalactan proteins 
differ. The reason for this variation is not clear. Some speculations can be offered 
as explanations. A basic assumption in the following remarks is that the plasma- 
cytomas are related to normal natural antibody-producing cells.  Indirect evi- 
dence supporting this notion has previously been described (22, 23). If so, then a 
specific antigen-binding myeloma population indirectly reflects an antigen se- 
lected population of cells. 
It may be argued that the variations we have observed originated by a mecha- 
nism different from activation of unique pairs of germ line VL and VH genes. 
These changes may have resulted from some form of somatic mutational mecha- 
nism that is imposed on germ line genes. The sequence variations which we 
have found in the VII chains in fact suggest this possibility since they can be in- 
terpreted as resulting from single point mutations in the existing genes. It is 
then conceivable that  random mutations in  the  genes could affect the anti- 
genicity, but not the antigen-binding specificity of a given protein. Variations 
of this type could also affect binding but not to the degree that the protein could 
no longer be selected for by specific antigen. In this connection it is interesting 
to note that in a previous study we have found differences in the fluorescence of 
3  Barstad, P., S. Rudikoff,  L. Hood, M. Potter, W. Konigsberg,  and M. Cohn. Manuscript 
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three of the six proteins reported here on binding with 8-(1 ~  6)-9-galactotriose 
and galactotetraose (7). 
From the differences observed in the fluorescence properties on binding of 
hapten (7) it seems safe to assume that some of the variation among these pro- 
teins will be found in r~.sidues that are either part of the binding site or which 
contribute indirectly to the structure of the combining site. In addition, other 
differences may be found in amino acids which do not contribute to the struc- 
rure of the combining site. The two interchanges described in the heavy chain 
aminoterminal sequences might be examples of sustitutions which are not con- 
cerned with the structure of the site. Most studies to date indicate that site-re- 
lated amino acids, i.e., amino acids in the hypervariable regions and amino acids 
which have been affinity site labeled (24-28)  are  not  located  in  the  amino- 
terminal portion of either the light or heavy chain. Substitutions in the amino- 
terminal sequences of the heavy chain might, however, contribute to the indi- 
vidual antigenic specificity of these proteins. 
It is interesting to compare the results obtained from the mouse phosphoryl- 
choline and galactan systems with those of the human monoclonal cold agglu- 
tinin  and  antigamma globulin systems.  Human  cold  agglutinins have  been 
found to fall into three major groups sharing idiotypic specificities (29).  Capra 
et al.  (30) determined the aminoterminal sequences of 10 kappa chains from 
IgM cold agglutinins and found 7 to fall in the VKHI subgroup. Of these three 
had identical sequences and three others differed by single substitutions. 
Human proteins with antigamma globulin activity can also be divided into 
groups demonstrating shared idiotypic specificity. Although each protein has 
been shown to possess individual antigenic specificities, two groups have emerged 
with shared specificities (31). Two of the proteins found in the same idiotypic 
specificity group, Lay and Pom, with the exception of an unusual Ala NH2 termi- 
nal residue in the Lay protein, have only a single difference in the first 40 resi- 
dues of their heavy chains (which includes the first hypervariable region) al- 
though the light chains are from entirely different subgroups. Two other VKI 
light chains from antigamma globulin proteins, Dav and Fin, have identical se- 
quences through the first hypervariable region  (32).  Thus, many similarities 
can be found in both the mouse and human systems. Detailed studies of these 
systems should provide  further insight  into  structure-function relationships 
and the variations in antibody specificity. 
SUMMARY 
Six IgA myeloma proteins of BALB/c origin which bind antigens containing 
fl-(1 --~ 6)-n-galactan side chains  have been  isolated  by affinity chromatog- 
raphy on galactoside-BSA-Sepharose columns. Partial amino acid sequences of 
of the light chains to residue Cys23 and the heavy chains to reside 30 were de- 
termined on the automated sequencer. No differences were found among the six 
VK sequences. Among some 50 partial V~ sequences that have thus far been de- 1104  GALACTAN-BINDING  MYELOMA  PROTEINS 
termined these six chains are the only ones thus far identified in this subgroup; 
at least 25 V~ subgroups in the mouse have been identified so far. The heavy 
chain partial sequences were also very closely related but two differences were 
found. One protein differed from the other five by having isoleucine instead of 
leucine at position 5, a second protein differed from the others by having an un- 
identified  amino  acid  at  position  19.  Using  the  highly sensitive  inhibition  of 
hemagglutination  method it was found that  each of the proteins possessed  a 
unique inidividual antigenic determinant. 
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